A randomized, double-blind, placebo-controlled, time-lagged, parallel-group, ascending single and multiple oral dose study of the safety, tolerability, pharmacokinetics and pharmacodynamics of LAF237 [vildagliptin] in Chinese healthy subjects
Latest Information Update: 24 Apr 2013
At a glance
- Drugs Vildagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Sponsors Novartis
- 21 Jun 2007 Status change from in progress to completed
- 06 Feb 2007 New trial record.